The FDA is seeking public comments and data on early-phase clinical trial designs for ibogaine drug products, including dosing, safety monitoring and oversight.

The FDA’s request for information covers study populations, dose selection and escalation, care settings, safety monitoring, eligibility, stopping rules, informed consent and independent oversight. Comments, data and information can be submitted for 45 days after Federal Register publication, with the period closing on 20 November 2026.